Publicis Health's live pitchfest, with celeb judges and an audience of pharma and ad insiders, crowned a smart device as winner.

Rather than routine use, Kisqali’s coverage on NHS is available only through the Cancer Drugs Fund, the same limitation Verzenio got in the field.

Evoke is continuing to grow its talent with the hire of Jennifer O’Dwyer as its new president of North America.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

They say a picture’s worth a thousand words, and Sanofi and Regeneron are using that exchange rate to their advantage with Libtayo.

Biohaven could soon go up against large drugmakers' CGRP injectables Aimovig, Ajovy and Emgality with its oral drug rimegepant.

AbbVie remained the top pharma TV ad spender in June, and Gilead continued its HIV TV push. But one longtime ranker dropped out of sight.

At least based on recent IQVIA data, analysts suspect that Dovato will be of threat to Gilead any time soon.